NGS Oncology Market Report 2026

The ngs oncology market size has grown rapidly in recent years. It will grow from $19.33 billion in 2025 to $21.54 billion in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to declining sequencing costs, rising global cancer prevalence, increased oncology research funding, early adoption of targeted therapies, growth of genomic research initiatives.

The ngs oncology market size is expected to see rapid growth in the next few years. It will grow to $32.87 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to expansion of precision oncology programs, growing demand for personalized cancer treatment, increasing approvals of ngs-based diagnostics, advancements in bioinformatics analytics, integration of ngs into clinical guidelines. Major trends in the forecast period include expansion of comprehensive tumor profiling, rising adoption of liquid biopsy NGS, increasing clinical utility of multi-gene panels, integration of NGS in routine oncology diagnostics, growing demand for faster turnaround sequencing workflows.

The increasing prevalence of cancer is expected to drive the growth of the NGS oncology market in the coming years. Cancer is a disease characterized by the uncontrolled growth of abnormal cells that can spread to other parts of the body, interfering with normal physiological functions. The rising burden of cancer is largely attributed to factors such as aging and growing populations, along with heightened exposure to risk factors including tobacco use, alcohol consumption, obesity, and air pollution. NGS oncology plays a crucial role in public health and patient care by enabling early detection, accurate diagnosis, and personalized treatment through comprehensive genetic profiling of tumors. For example, in January 2024, according to data released by the American Cancer Society, a U.S.-based non-profit organization, the United States is projected to record 2,001,140 new cancer cases and 611,720 cancer-related deaths in 2024, compared with 1,958,310 cases and 609,820 deaths in 2023. As a result, the growing prevalence of cancer is contributing to the expansion of the NGS oncology market.

Major companies operating in the NGS oncology market are concentrating on the development of innovative solutions, such as liquid biopsy research assays, to support non-invasive and real-time cancer detection and monitoring through the analysis of circulating tumor DNA. A liquid biopsy research assay is a diagnostic approach that examines biological fluids, including blood, to identify genetic mutations or molecular markers linked to cancer, enabling minimally invasive detection and disease monitoring. For instance, in August 2024, Illumina Inc., a U.S.-based biotechnology company specializing in next-generation sequencing technologies, expanded its oncology portfolio for NovaSeq X Series users. The company introduced the newly validated high-throughput TruSight Oncology 500 HT (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These advanced assays allow laboratories to enhance oncology research for both tissue and liquid biopsy samples by offering improved sequencing efficiency, shorter run times, and the capacity to process larger sample volumes on the NovaSeq X Series for the first time.

In December 2024, Deerfield Management Company, a U.S.-based investment firm, completed the acquisition of Singular Genomics for an undisclosed amount. Through this acquisition, Deerfield Management Company aims to strengthen its research and clinical capabilities by integrating Singular Genomics’ next-generation sequencing and spatial multiomics technologies. Singular Genomics is a U.S.-based biotechnology company focused on the development of next-generation sequencing and multiomics solutions.

Major companies operating in the ngs oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc, Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

North America was the largest region in the NGS oncology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ngs oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ngs oncology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the NGS oncology market by increasing the cost of imported sequencing instruments, reagents, and consumables, leading to higher operational expenses for laboratories and research centers. The impact is most pronounced across sequencing platforms, kits, and data analysis tools, particularly in regions dependent on imports such as asia-pacific and parts of europe. Hospitals, research institutes, and biotechnology companies face procurement delays and budget constraints due to these trade barriers. However, tariffs have also encouraged localized manufacturing, regional supply chain development, and strategic partnerships, supporting long-term market resilience and innovation.

The ngs oncology market research report is one of a series of new reports that provides ngs oncology market statistics, including ngs oncology industry global market size, regional shares, competitors with a ngs oncology market share, detailed ngs oncology market segments, market trends and opportunities, and any further data you may need to thrive in the ngs oncology industry. This ngs oncology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Next-generation sequencing (NGS) oncology involves the application of advanced sequencing technologies to examine the genetic composition of cancer cells. It enables the detection of specific mutations, genetic changes, and biomarkers that support the development of personalized treatment strategies, help predict therapeutic responses, and enhance the overall management of cancer patients. NGS oncology supports precision medicine by allowing treatments to be customized according to the tumor’s genetic profile.

The key sequencing technologies in NGS oncology include targeted sequencing, genomics, transcriptomics, and epigenomics. Targeted sequencing is a genomic approach that concentrates on analyzing selected genes or specific regions of the genome to identify genetic variations associated with diseases or traits. These technologies are delivered through platforms, kits, and services, with workflows that include pre-sequencing, sequencing, and data analysis stages. They are applied across multiple areas such as genetic screening, hereditary genetic testing, hematological malignancies, solid tumors, and others, and are used by end users including hospitals and clinics, clinical research organizations (CROs), academic and research institutions, pharmaceutical companies, biotechnology firms, and others.

The NGS oncology market consists of revenues earned by entities by providing services such as companion diagnostics, liquid biopsy analysis, genetic mutation analysis, bioinformatics, and data interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. The NGS oncology market also includes sales of target enrichment kits, library preparation kits, data analysis pipelines, bioinformatics software, and tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.